Document is current
Any future updates will be listed below
-
Authors
Laguna-Muñoz, David
Jiménez-Peinado, Ana
Jaén-Moreno, María José https://orcid.org/0000-0003-0905-901X
Camacho-Rodríguez, Cristina
del Pozo, Gloria Isabel
Vieta, Eduard https://orcid.org/0000-0002-0548-0053
Caballero-Villarraso, Javier https://orcid.org/0000-0003-0571-5147
Khan, Muhammad Ijlal
Rico-Villademoros, Fernando
Sarramea, Fernando
- License Information
-
More Information
Article History
Received: 4 March 2024
Revised: 30 September 2024
Accepted: 9 October 2024
First Online: 14 November 2024
Competing interests
: EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, AbbVie, Adamed, Angelini, Biogen, Beckley-Psytech, Biohaven, Boehringer-Ingelheim, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Idorsia, Johnson & Johnson, Lundbeck, Luye Pharma, Medincell, Merck, Newron, Novartis, Orion Corporation, Organon, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, Teva, and Viatris, outside the submitted work. FS during the last 5 years has been speaker for Rovi and Janssen-Cilag. DL-M during the last 5 years has been speaker for Lundbeck. All other authors report no biomedical financial interests or potential conflicts of interests related with this manuscript.
